title: Effect of neonatal gene therapy on lumbar spine disease in mucopolysaccharidosis VII dogs.
abstract: Mucopolysaccharidosis VII (MPS VII) is due to deficient β-glucuronidase (GUSB) activity, which leads to accumulation of chondroitin, heparan, and dermatan sulfate glycosaminoglycans in various tissues including those of the spine. Associated spine disease can be due to abnormalities in the vertebrae, the intervertebral disks, or other spine tissues. The goal of this study was to determine if neonatal gene therapy could prevent lumbar spine disease in MPS VII dogs. MPS VII dogs were injected intravenously with a retroviral vector (RV) expressing canine GUSB at 2 to 3 days after birth, which resulted in transduction of hepatocytes that secreted GUSB into blood. Expression was stable for up to 11 years, and mean survival was increased from 0.4 years in untreated dogs to 6.1 years in treated dogs. Despite a profound positive clinical effect, 6-month-old RV-treated MPS VII dogs still had hypoplastic ventral epiphyses with reduced calcification in the lumbar spine, which resulted in a reduced stiffness and increased range of motion that were not improved relative to untreated MPS VII dogs. At six to 11 years of age, ventral vertebrae remained hypoplastic in RV-treated MPS VII dogs, and there was desiccation of the nucleus pulposus in some disks. Histochemical staining demonstrated that disks did not have detectable GUSB activity despite high serum GUSB activity, which is likely due to poor diffusion into this relatively avascular structure. Thus, neonatal gene therapy cannot prevent lumbar spine disease in MPS VII dogs, which predicts that enzyme replacement therapy (ERT) will similarly be relatively ineffective even if started at birth.
authors.affiliation: Department of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA. lachlans@mail.med.upenn.edu
authors.forename: Lachlan J
authors.initials: LJ
authors.lastname: Smith
authors.forename: John T
authors.initials: JT
authors.lastname: Martin
authors.forename: Patricia
authors.initials: P
authors.lastname: O'Donnell
authors.forename: Ping
authors.initials: P
authors.lastname: Wang
authors.forename: Dawn M
authors.initials: DM
authors.lastname: Elliott
authors.forename: Mark E
authors.initials: ME
authors.lastname: Haskins
authors.forename: Katherine P
authors.initials: KP
authors.lastname: Ponder
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D000831:Animals, Newborn; D001696:Biomechanical Phenomena; D002118:Calcium / Q000378:metabolism; D004285:Dogs; D015316:Genetic Therapy; D005822:Genetic Vectors / Q000008:administration & dosage / Q000235:genetics; D005966:Glucuronidase / Q000097:blood; D006025:Glycosaminoglycans / Q000652:urine; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology; D008297:Male; D016538:Mucopolysaccharidosis VII / Q000150:complications* / Q000401:mortality / Q000628:therapy*; D011859:Radiography; D012190:Retroviridae / Q000235:genetics; D013122:Spinal Diseases / Q000175:diagnosis / Q000209:etiology* / Q000628:therapy*
chemical_list: D006025:Glycosaminoglycans; D005966:Glucuronidase; D002118:Calcium